{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:05:34Z","timestamp":1793397934276,"version":"4.5.0"},"reference-count":78,"publisher":"American Medical Association (AMA)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,4,25]]},"abstract":"<jats:sec id=\"ab-jrv230008-1\"><jats:title>Importance<\/jats:title><jats:p>Pituitary adenomas are neoplasms of the pituitary adenohypophyseal cell lineage and include functioning tumors, characterized by the secretion of pituitary hormones, and nonfunctioning tumors. Clinically evident pituitary adenomas occur in approximately 1 in 1100 persons.<\/jats:p><\/jats:sec><jats:sec id=\"ab-jrv230008-2\"><jats:title>Observations<\/jats:title><jats:p>Pituitary adenomas are classified as either macroadenomas (\u226510 mm) (48% of tumors) or microadenomas (&amp;amp;lt;10 mm). Macroadenomas may cause mass effect, such as visual field defects, headache, and\/or hypopituitarism, which occur in about 18% to 78%, 17% to 75%, and 34% to 89% of patients, respectively. Thirty percent of pituitary adenomas are nonfunctioning adenomas, which do not produce hormones. Functioning tumors are those that produce an excess of normally produced hormones and include prolactinomas, somatotropinomas, corticotropinomas, and thyrotropinomas, which produce prolactin, growth hormone, corticotropin, and thyrotropin, respectively. Approximately 53% of pituitary adenomas are prolactinomas, which can cause hypogonadism, infertility, and\/or galactorrhea. Twelve percent are somatotropinomas, which cause acromegaly in adults and gigantism in children, and 4% are corticotropinomas, which secrete corticotropin autonomously, resulting in hypercortisolemia and Cushing disease. All patients with pituitary tumors require endocrine evaluation for hormone hypersecretion. Patients with macroadenomas additionally require evaluation for hypopituitarism, and patients with tumors compressing the optic chiasm should be referred to an ophthalmologist for formal visual field testing. For those requiring treatment, first-line therapy is usually transsphenoidal pituitary surgery, except for prolactinomas, for which medical therapy, either bromocriptine or cabergoline, is usually first line.<\/jats:p><\/jats:sec><jats:sec id=\"ab-jrv230008-3\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Clinically manifest pituitary adenomas affect approximately 1 in 1100 people and can be complicated by syndromes of hormone excess as well as visual field defects and hypopituitarism from mass effect in larger tumors. First-line therapy for prolactinomas consists of bromocriptine or cabergoline, and transsphenoidal pituitary surgery is first-line therapy for other pituitary adenomas requiring treatment.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2023.5444","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T15:39:15Z","timestamp":1682437155000},"page":"1386","source":"Crossref","is-referenced-by-count":326,"title":["Diagnosis and Management of Pituitary Adenomas"],"prefix":"10.1001","volume":"329","author":[{"given":"Nicholas A.","family":"Tritos","sequence":"first","affiliation":[{"name":"Neuroendocrine Unit, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen K.","family":"Miller","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"jrv230008r1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review.","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"jrv230008r2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies.","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"jrv230008r3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.7326\/0003-4819-120-10-199405150-00001","article-title":"Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population.","volume":"120","author":"Hall","year":"1994","journal-title":"Ann Intern Med"},{"key":"jrv230008r4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/B978-0-444-59602-4.00012-5","article-title":"Nonfunctioning pituitary tumors.","volume":"124","author":"Molitch","year":"2014","journal-title":"Handb Clin Neurol"},{"issue":"12","key":"jrv230008r5","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium.","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"223","key":"jrv230008r6","first-page":"2172","article-title":"Epidemiology of pituitary adenoma: results of the first Swiss study.","volume":"5","author":"Fontana","year":"2009","journal-title":"Rev Med Suisse"},{"issue":"3","key":"jrv230008r7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/cen.2010.72.issue-3","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"jrv230008r8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","article-title":"Prevalence and incidence of pituitary adenomas: a population based study in Malta.","volume":"16","author":"Gruppetta","year":"2013","journal-title":"Pituitary"},{"issue":"5","key":"jrv230008r9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1530\/EJE-15-0189","article-title":"The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study.","volume":"173","author":"Agustsson","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"jrv230008r10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1017\/cjn.2015.301","article-title":"Sellar masses: an epidemiological study.","volume":"43","author":"Al-Dahmani","year":"2016","journal-title":"Can J Neurol Sci"},{"issue":"6","key":"jrv230008r11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1590\/2359-3997000000195","article-title":"Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a health management organization in Buenos Aires, Argentina.","volume":"60","author":"Day","year":"2016","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"jrv230008r12","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1210\/jc.2014-3787","article-title":"Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies.","volume":"100","author":"Pappachan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"jrv230008r13","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1210\/clinem\/dgac265","article-title":"The effect of endogenous Cushing syndrome on all-cause and cause-specific mortality.","volume":"107","author":"Limumpornpetch","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"jrv230008r14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ecl.2007.10.011","article-title":"Nonfunctioning pituitary tumors and pituitary incidentalomas.","volume":"37","author":"Molitch","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"13","key":"jrv230008r15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","article-title":"Clinical practice: prolactinomas.","volume":"362","author":"Klibanski","year":"2010","journal-title":"N Engl J Med"},{"issue":"9996","key":"jrv230008r16","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing\u2019s syndrome.","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"jrv230008r17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12020-016-0863-3","article-title":"Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management.","volume":"52","author":"Amlashi","year":"2016","journal-title":"Endocrine"},{"issue":"2","key":"jrv230008r18","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1530\/EJE-21-0162","article-title":"Endocrine tumours: thyrotropin-secreting pituitary adenoma: a structured review of 535 adult cases.","volume":"185","author":"De Herdt","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"jrv230008r20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma.","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr Rev"},{"issue":"9","key":"jrv230008r21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJM198608283150903","article-title":"Increase in bone mass after treatment of hyperprolactinemic amenorrhea.","volume":"315","author":"Klibanski","year":"1986","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv230008r22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ecl.2007.10.002","article-title":"Acromegaly.","volume":"37","author":"Ben-Shlomo","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"jrv230008r23","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1210\/jc.2017-02457","article-title":"Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature.","volume":"103","author":"Dal","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"jrv230008r24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ecl.2007.10.010","article-title":"Cushing\u2019s syndrome.","volume":"37","author":"Pivonello","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"jrv230008r25","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline.","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"jrv230008r26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"jrv230008r27","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an Endocrine Society clinical practice guideline.","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"jrv230008r28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1530\/EJE-10-0744","article-title":"Limited utility of oral glucose tolerance test in biochemically active acromegaly.","volume":"164","author":"Ribeiro-Oliveira","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"jrv230008r29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12020-018-1805-z","article-title":"Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?","volume":"64","author":"Dobri","year":"2019","journal-title":"Endocrine"},{"issue":"6","key":"jrv230008r30","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1210\/clinem\/dgaa105","article-title":"Accuracy of laboratory tests for the diagnosis of Cushing syndrome.","volume":"105","author":"Galm","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"jrv230008r31","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update.","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"jrv230008r32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3803\/EnM.2015.30.3.297","article-title":"Limited diagnostic utility of plasma adrenocorticotropic hormone for differentiation between adrenal Cushing syndrome and Cushing disease.","volume":"30","author":"Hong","year":"2015","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"2","key":"jrv230008r33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000351007","article-title":"2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors.","volume":"2","author":"Beck-Peccoz","year":"2013","journal-title":"Eur Thyroid J"},{"issue":"3","key":"jrv230008r34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ecl.2020.06.002","article-title":"Advances in the imaging of pituitary tumors.","volume":"49","author":"MacFarlane","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"key":"jrv230008r35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.807040","article-title":"Radiological Knosp, revised-Knosp, and Hardy-Wilson classifications for the prediction of surgical outcomes in the endoscopic endonasal surgery of pituitary adenomas: study of 228 cases.","volume":"11","author":"Araujo-Castro","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"jrv230008r36","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/cen.2006.65.issue-4","article-title":"Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? a study of 226 patients with histologically verified non-functioning pituitary macroadenoma.","volume":"65","author":"Karavitaki","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"jrv230008r37","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1210\/jc.2017-00696","article-title":"Effects of prednisolone on serum and tissue fluid IGF-I receptor activation and post-receptor signaling in humans.","volume":"102","author":"Ramshanker","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"jrv230008r38","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/cen.12556","article-title":"Clinical and genetic characteristics of a large monocentric series of patients affected by thyroid hormone (Th) resistance and suggestions for differential diagnosis in patients without mutation of Th receptor \u00df.","volume":"81","author":"Macchia","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"jrv230008r39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11102-011-0347-7","article-title":"Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.","volume":"15","author":"Roelfsema","year":"2012","journal-title":"Pituitary"},{"key":"jrv230008r40","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/j.wneu.2021.07.035","article-title":"Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis.","volume":"154","author":"Wright","year":"2021","journal-title":"World Neurosurg"},{"issue":"11","key":"jrv230008r41","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00701-016-2903-4","article-title":"Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis.","volume":"158","author":"Starnoni","year":"2016","journal-title":"Acta Neurochir (Wien)"},{"issue":"4","key":"jrv230008r42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11102-014-0602-9","article-title":"Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system.","volume":"18","author":"Nunes","year":"2015","journal-title":"Pituitary"},{"issue":"8","key":"jrv230008r43","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline.","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"jrv230008r44","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s11102-020-01066-8","article-title":"Outcomes of pituitary surgery for Cushing\u2019s disease: a systematic review and meta-analysis.","volume":"23","author":"Stroud","year":"2020","journal-title":"Pituitary"},{"issue":"1","key":"jrv230008r45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/2046-4053-1-33","article-title":"Treatment of hyperprolactinemia: a systematic review and meta-analysis.","volume":"1","author":"Wang","year":"2012","journal-title":"Syst Rev"},{"issue":"3","key":"jrv230008r46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ecl.2020.05.006","article-title":"The role of dopamine agonists in pituitary adenomas.","volume":"49","author":"Giraldi","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"jrv230008r47","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-21-0462","article-title":"ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy.","volume":"185","author":"Luger","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"jrv230008r48","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients: a systematic review and meta-analysis.","volume":"105","author":"Zamanipoor Najafabadi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"jrv230008r49","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.","volume":"99","author":"Carmichael","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"jrv230008r50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly.","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"jrv230008r51","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.","volume":"100","author":"Melmed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"jrv230008r52","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"jrv230008r53","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis.","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"jrv230008r54","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"16","key":"jrv230008r55","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"issue":"9295","key":"jrv230008r56","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"jrv230008r57","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","article-title":"Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis.","volume":"21","author":"Broersen","year":"2018","journal-title":"Pituitary"},{"issue":"11","key":"jrv230008r58","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"jrv230008r59","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"jrv230008r60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/js.2018-00269","article-title":"Continuous etomidate infusion for the management of severe Cushing syndrome: validation of a standard protocol.","volume":"3","author":"Carroll","year":"2018","journal-title":"J Endocr Soc"},{"issue":"6","key":"jrv230008r61","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome.","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"jrv230008r62","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.jval.2017.12.014","article-title":"Medical treatments for acromegaly: a systematic review and network meta-analysis.","volume":"21","author":"Leonart","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"jrv230008r63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines.","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"9","key":"jrv230008r64","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial.","volume":"105","author":"Bonert","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"jrv230008r65","doi-asserted-by":"publisher","first-page":"454","DOI":"10.4158\/EP-2019-0528","article-title":"Comparative efficacy of medical treatment for acromegaly: a systematic review and network meta-analysis of integrated randomized trials and observational studies.","volume":"26","author":"Qiao","year":"2020","journal-title":"Endocr Pract"},{"issue":"4","key":"jrv230008r66","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update.","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"jrv230008r67","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing\u2019s disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"jrv230008r68","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating Cushing\u2019s syndrome: a retrospective multicenter study in 195 patients.","volume":"100","author":"Daniel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"jrv230008r69","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1530\/EJE-12-0358","article-title":"Efficiency and tolerance of mitotane in Cushing\u2019s disease in 76 patients from a single center.","volume":"167","author":"Baudry","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"jrv230008r70","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1530\/EJE-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease.","volume":"163","author":"Godbout","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"jrv230008r71","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease.","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv230008r72","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","article-title":"Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial.","volume":"6","author":"Lacroix","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"jrv230008r73","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1210\/jc.2011-0251","article-title":"Radiation therapy in the management of pituitary adenomas.","volume":"96","author":"Loeffler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"jrv230008r74","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3171\/2021.2.JNS204440","article-title":"Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and International Stereotactic Radiosurgery Society practice recommendations.","volume":"136","author":"Mathieu","year":"2021","journal-title":"J Neurosurg"},{"issue":"4","key":"jrv230008r75","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1210\/jc.2010-1054","article-title":"Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis.","volume":"96","author":"Fern\u00e1ndez-Balsells","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"jrv230008r76","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-18-0255","article-title":"Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis.","volume":"179","author":"Bolfi","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"jrv230008r77","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","article-title":"Mortality in patients with Cushing\u2019s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study.","volume":"4","author":"Clayton","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"jrv230008r78","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa291","article-title":"Excess morbidity persists in patients with Cushing\u2019s disease during long-term remission: a Swedish nationwide study.","volume":"105","author":"Papakokkinou","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"jrv230008r19","first-page":"58","article-title":"Prolactin and its role in human reproduction.","volume-title":"Yen and Jaffe\u2019s Reproductive Endocrinology","author":"Tritos","year":"2018","edition":"8th ed"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2804060\/jama_tritos_2023_rv_230008_1681934394.0467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T15:39:21Z","timestamp":1682437161000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2804060"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":78,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,4,25]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.5444","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,25]]}}}